Most Read

This follows the company’s signing of a definitive agreement in October 2025 to acquire the business. The deal adds advanced Protein A chromatography capabilities and Amsphere Protein A

Under the agreement, Biocytogen’s fully human antibody discovery platform will be combined with Sihuan Pharmaceutical’s capabilities in drug development, manufacturing, and commercialisation. The collaboration will focus on advanced

The IND includes results from completed toxicology, pharmacology, and manufacturing studies necessary for regulatory assessment. Pending IND clearance, Telomir Pharmaceuticals aims to start a Phase I/II clinical trial

The partnership aims to explore a new class of small molecules, called molecular glues, which enable or stabilise interactions between proteins. Molecular glues are an emerging therapeutic modality

The FDA approval of Ponlimsi is based on a comprehensive evidence package, including analytical and clinical data showing immunogenicity, safety, and similar efficacy to Prolia. Ponlimsi is approved

The partnership focuses on progressing Cellinfinity BIO’s programmes CIB-301 and CIB-350. uBriGene’s LVV Turbo platform will provide good manufacturing practice (GMP) lentiviral vector manufacturing, production, process development, and

The deal is anticipated to close in the second quarter of 2026, subject to standard conditions. The acquisition aims to expand Otsuka’s portfolio in the psychiatric and neurological

It is indicated as an adjunct to exercise and diet for improving glycaemic control. The FDA’s decision is based on data from the ONWARDS Phase IIIa clinical programme,

The acquisition will provide access to Exl-111, a half-life extended, high-affinity anti-IgE antibody currently in Phase I clinical trials. Designed as an advanced extension of the established biology